WEBULL
WebtradeDownload

Shandong Xinhua Pharmaceutical (SEHK:719) Q3 Earnings Echo A Margin Squeeze

Simply Wall St · 3d ago

Shandong Xinhua Pharmaceutical came into this Q3 2026 earnings release with a stock that had drifted, down about 11.7% over the past three months and roughly flat over the last week, yet carrying a trailing P/E of 14x and trading about 27.9% below a reference discounted cash flow value. The new quarter did not resolve that tension. Revenue printed at CN¥1,703.3m and net income excluding one off items was CN¥45.9m, both softer than in Q2. This puts the pressure squarely on profitability rather than the balance sheet or top line.

Like the valuation setup on Shandong Xinhua Pharmaceutical but uneasy about the earnings softness this quarter and the pressure on profitability? You can filter for peers that combine stronger margins with sturdier fundamentals in our list of solid balance sheet and fundamentals stocks (205 results)

Q3 2026 Earnings Summary

  • Total Revenue (Q3 2026 vs Q3 2025): CN¥1,703.3m vs. CN¥2,123.8m (down about 19.8%)
  • Net Income Excl. Extra Items (Q3 2026 vs Q3 2025): CN¥45.9m vs. CN¥32.5m (up about 41.5%)
  • Basic EPS (Q3 2026 vs Q3 2025): CN¥0.0658 vs. CN¥0.0464 (up about 41.8%)
  • Trailing 12 Month Net Profit Margin (Q3 2026 vs prior year): 2.8% vs. 4.5% (margin compressed)

Ask Charlie what Shandong Xinhua’s valuation gap really reflects.

SEHK:719 Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
SEHK:719 Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

Profit Mix Keeps Shandong Xinhua Pharma Bulls Interested

For a bullish angle on Shandong Xinhua Pharmaceutical, the appeal is earnings power holding up better than sales. Revenue for Q3 fell sharply year on year, yet net income excluding one off items and basic EPS both improved. That points to tighter cost control or a richer product mix. Recent approvals for Nimodipine and Sacubitril Valsartan Sodium fit a story in which new, reimbursed drugs can support earnings quality even when headline sales come under pressure.

Revenue Slide And Margin Compression Feed Caution

On the flip side, the bearish concerns around pressure in generics and APIs look grounded. Top line for Q3 2026 declined almost 20% versus Q3 2025, while the trailing 12 month net profit margin compressed from 4.5% to 2.8%. That combination signals weaker pricing or higher input costs biting into returns. Recent share performance, down over 11% across three months, shows investors already reacting to this squeeze, even with new product launches entering the portfolio.

After compressed margins, shrinking revenue and an unstable dividend history at Shandong Xinhua Pharmaceutical, it is fair to ask whether these are isolated issues or part of a deeper pattern. Review the structured warning signs already mapped in our risk analysis for Shandong Xinhua Pharmaceutical which shows 4 important warning signs.

Hunt For Mispriced Earnings Power

Shandong Xinhua Pharmaceutical shows how revenue pressure can coexist with a very different profit profile. The real opportunity could be finding stocks that look misaligned before valuations adjust.

  • Company 1 - 44% below our estimate - uses a large retail and corporate footprint to grow fee income and cut costs on a shared technology platform.
  • Company 2 - 30% below our estimate - shifts its mix toward higher margin specialty products as new defense and nutrition capacity ramps against weaker basic chemical demand.
  • Company 3 - 39% below our estimate - treats recent free cash flow strength as a test of whether reduced debt and service growth can hold through the machinery cycle.

That is three of the list. See every one of the 190 undervalued companies on it →